Blue Jet Healthcare Q2 profit nearly doubles as revenue jumps

Blue Jet Healthcare Limited reported unaudited standalone profit after tax of Rs 102.52 crore for the quarter ended September 30, 2026, up 96.6% from Rs 52.14 crore a year earlier, as revenue from operations rose 127.1% to Rs 375.74 crore. The board approved the results on November 5, 2026.

How much did Blue Jet Healthcare earn in Q2 FY27?

Blue Jet Healthcare earned Rs 102.52 crore in profit after tax for the three months ended September 30, 2026, compared with Rs 52.14 crore in the corresponding quarter a year earlier. Profit before tax rose to Rs 137.39 crore from Rs 68.73 crore, while total income increased to Rs 401.95 crore from Rs 189.75 crore.

Revenue from operations reached Rs 375.74 crore in the September 2026 quarter, against Rs 165.48 crore in the September 2025 quarter. Other income was Rs 26.21 crore, compared with Rs 24.27 crore a year earlier, so the larger part of the increase in total income came from operations. Basic and diluted earnings per share were Rs 5.46, versus Rs 3.01; the company said interim earnings per share are not annualised.

What changed from the June 2026 quarter?

Blue Jet Healthcare’s revenue from operations increased 28.2% from Rs 293.11 crore in the three months ended June 30, 2026, to Rs 375.74 crore in the September quarter. Profit after tax rose 31.0% from Rs 78.26 crore, and profit before tax increased 29.7% from Rs 105.95 crore.

Total income rose by Rs 93.60 crore sequentially to Rs 401.95 crore, while total expenses increased by Rs 62.16 crore to Rs 264.56 crore. Other income increased to Rs 26.21 crore from Rs 15.24 crore, and the difference between the income and expense increases was reflected in the higher profit before tax.

Cost of materials consumed rose to Rs 201.64 crore from Rs 178.88 crore between the June and September 2026 quarters. The company recorded a Rs 8.30 crore decrease in inventories of finished goods and work-in-progress in the September quarter, compared with a Rs 41.77 crore decrease in the June quarter, while employee-benefit expense was Rs 20.41 crore against Rs 20.12 crore.

Which costs moved with Q2 revenue growth?

Blue Jet Healthcare’s total expenses increased 118.6% year-on-year to Rs 264.56 crore in the September 2026 quarter, from Rs 121.03 crore in the September 2025 quarter. Cost of materials consumed, the largest stated expense, increased to Rs 201.64 crore from Rs 108.42 crore as revenue from operations grew by Rs 210.26 crore.

Other expenses rose to Rs 43.25 crore from Rs 34.11 crore, employee-benefit expense increased to Rs 20.41 crore from Rs 18.55 crore, and depreciation and amortisation reached Rs 6.92 crore from Rs 5.87 crore. Finance costs moved in the other direction, falling to Rs 0.64 crore from Rs 4.63 crore.

Tax expense was Rs 34.88 crore in the September 2026 quarter, compared with Rs 16.59 crore a year earlier. Current tax accounted for Rs 33.17 crore, while deferred tax was a Rs 1.71 crore charge; the earlier quarter had a Rs 1.32 crore deferred-tax credit. Profit after tax consequently increased by Rs 50.38 crore year-on-year.

What do the first-half results and balance sheet show?

Blue Jet Healthcare reported revenue from operations of Rs 668.86 crore for the six months ended September 30, 2026, up 28.6% from Rs 520.24 crore in the corresponding six months of 2025. First-half profit after tax rose 26.2% to Rs 180.78 crore from Rs 143.31 crore, while profit before tax increased to Rs 243.34 crore from Rs 191.59 crore.

First-half total expenses were Rs 466.96 crore, compared with Rs 361.18 crore a year earlier. Materials consumed rose to Rs 380.51 crore from Rs 216.31 crore, whereas finance costs fell to Rs 1.30 crore from Rs 5.32 crore. The first-half revenue growth rate was below the September-quarter rate because revenue in the June 2026 quarter was Rs 293.11 crore.

Total assets stood at Rs 2,583.88 crore at September 30, 2026, compared with Rs 1,641.16 crore at March 31, 2026. Current assets rose to Rs 1,795.93 crore from Rs 957.04 crore, including Rs 604.60 crore of current investments, Rs 444.65 crore of trade receivables and Rs 251.26 crore of inventories.

Total equity increased to Rs 2,298.59 crore at September 30, 2026, from Rs 1,359.91 crore at March 31, 2026. Capital work in progress rose to Rs 357.87 crore from Rs 301.38 crore, property, plant and equipment increased to Rs 267.85 crore from Rs 252.91 crore, and total current liabilities were Rs 232.67 crore against Rs 227.46 crore.

What was Blue Jet Healthcare’s September 2026 share issue?

Blue Jet Healthcare allotted 1,58,10,276 equity shares through a qualified institutional placement during the quarter ended September 30, 2026. The shares, with a face value of Rs 2 each, were issued to eligible qualified institutional buyers at Rs 506 per share, including a premium of Rs 504 per share.

The qualified institutional placement aggregated Rs 800 crore, according to the company’s results note. Paid-up equity share capital was Rs 37.86 crore at September 30, 2026, compared with Rs 34.69 crore at June 30, 2026 and September 30, 2025.

Blue Jet Healthcare manufactures artificial sweetener, contrast media intermediate, pharma intermediate and active pharmaceutical ingredients, or APIs, for pharmaceutical and healthcare products. It treats these activities as one reportable business segment under Indian Accounting Standard 108, and reported no subsidiaries, associates or joint ventures as of September 30, 2026.

Conclusion

Blue Jet Healthcare’s September 2026 quarter combined a Rs 210.26 crore year-on-year increase in revenue from operations with a Rs 50.38 crore increase in profit after tax. Total expenses rose by Rs 143.53 crore, led by materials consumed, while finance costs fell by Rs 3.99 crore and profit before tax nearly doubled to Rs 137.39 crore.

The next results will show whether the September-quarter revenue level follows the Rs 668.86 crore recorded in the first half ended September 30, 2026. Investors can also monitor changes in the Rs 800 crore qualified institutional placement balance-sheet effect, capital work in progress of Rs 357.87 crore and trade receivables of Rs 444.65 crore, as the filing did not specify the use of the placement proceeds.